





Showcasing research from Hu-Zhi Zheng's laboratory,
Department of Chemistry and Chemical Engineering,
Southwest University, Chongqing, China.

A H^+ -triggered bubble-generating nanosystem for killing
cancer cells

We established a H^+ -triggered bubble-generating nanosystem (BGNS) which can release gas bubbles quickly in the acidic environment of lysosomes, and hence successfully overcame multidrug resistance of cancer cells by enhancing the lysosome membrane permeabilization of cancer cells.

As featured in:



See Huzhi Zheng et al.,
Chem. Commun., 2016, **52**, 10838.



www.rsc.org/chemcomm

Registered charity number: 207890

COMMUNICATION

CrossMark
click for updatesA H⁺-triggered bubble-generating nanosystem for killing cancer cells†Cite this: *Chem. Commun.*, 2016, 52, 10838Received 29th May 2016,
Accepted 27th July 2016

DOI: 10.1039/c6cc04511a

www.rsc.org/chemcomm

Lili Yang,^a Zuhuang Wen,^a Yijuan Long,^a Ning Huang,^b Yuan Cheng,^b Li Zhao^c and Huzhi Zheng^{*a}

We constructed a H⁺-triggered bubble-generating nanosystem (BGNS), which generated CO₂ bubbles in the acidic environment of lysosomes after being internalized by cancer cells. The quickly generated bubbles caused enhanced lysosomal membrane permeabilization. As expected, H⁺-triggered BGNS possessed remarkable cytotoxicity against MCF-7 breast cancer cells, and successfully overcame the multidrug resistance of MCF-7/ADR cells.

Chemotherapy is one of the most common treatments for cancer; however, multidrug resistance (MDR) remains a significant obstacle for the effective treatment of this disease.^{1–3} To address this formidable challenge, diverse cancer therapies, such as photodynamic therapy,⁴ nucleic-targeted⁵ or nanocarrier-based drug delivery systems,⁶ bacteria⁷ or viral-based⁸ therapy, and short interfering RNAs for cancer gene therapy,⁹ have been developed to efficiently overcome the MDR of cancer cells. Lysosomes have been defined as “suicide bags.”¹⁰ As lysosomal membrane permeabilization (LMP) occurs, the release of certain cathepsins from the lysosome into the cytoplasm is thought to trigger cell death by apoptosis and apoptosis-like pathways.^{11,12} So, these organelles have gained much attention as potential therapeutic targets in cancer.^{13–15} In this work, we constructed a novel H⁺-triggered bubble-generating nanosystem (BGNS), which could enhance LMP by generating CO₂ bubbles. Certain cathepsins release from the lysosome into the cytoplasm, triggering cell death by apoptosis and apoptosis-like pathways due to upregulation of active caspase-3. The direct lysosome-targeted BGNS successfully bypassed the drug efflux pump, leading to enhanced apoptosis of MCF-7/ADR cells and the much efficient overcoming of MDR.

Incidentally, we found that doxorubicin (DOX), a widely used antitumor drug, reacts with NaHCO₃ to produce a red precipitate (Fig. S1, ESI†). In order to eliminate the interference of hydroxyl, we added DOX to sodium hydroxide solution (pH 8.5), which has the same pH as 0.2 mol L^{−1} NaHCO₃, and found no precipitate (Fig. S1, ESI†). This demonstrates that the red precipitate was bicarbonate, and not hydroxide precipitate. In addition, the red precipitate could be dissolved in an acidic phosphate buffer solution (PBS, pH 5.0) and generated bubbles. Based on these findings, we developed pH-responsive BGNS that could enhance LMP by generating CO₂ bubbles.

Among the diverse nanomaterials used in therapeutic systems, hollow mesoporous silica nanoparticles (HMSNs) have substantial significance in nanobiomedical research because of their large surface area, high pore volume, tunable pore sizes, and excellent biocompatibility.^{16–19} We chose HMSNs as a platform to establish BGNS. Monodispersed HMSNs can be readily synthesized by an improved selective etching process.²⁰ Transmission electron microscopy (TEM) showed that the HMSNs possessed a highly uniform and monodispersed spherical morphology with a distinctive hollow nanostructure (Fig. S2a, ESI†) and an average diameter and a wall thickness of 308 nm and 48 nm, respectively. Nitrogen adsorption desorption isotherm measurements showed that they had a specific surface area of 1.04 × 10^{−2} m² g^{−1} and well defined pore sizes of 10.2 nm (Fig. S2b, ESI†).

To establish BGNS, first we incubated DOX with HMSNs and obtained DOX-loaded HMSNs (DMSNs), after which we treated the DMSNs with NaHCO₃. The loading efficiency of DOX in DMSNs and BGNS was 5.3% and 16.8%, respectively. The electrostatic interaction between the positively charged DOX molecules and the negatively charged silica surface is the main force for drug loading.²¹ After treating the DMSNs with NaHCO₃, the loaded DOX molecules formed a DOX-HCO₃ precipitate and leave from the interior silica surface to the hollow cavity. Thus, the silica surface of BGNS was able to load more DOX.

The release rate of DOX from BGNS was lower than that from DMSNs in PBS at pH 7.4, which simulated normal physiological conditions (Fig. 1a). Conversely, the release of DOX from BGNS

^a Key Laboratory on Luminescent and Real-Time Analytical Chemistry (Southwest University), College of Chemistry and Chemical Engineering, Southwest University, Beibei, Chongqing, 400715, China. E-mail: zhenghz@swu.edu.cn

^b Department of Neurosurgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, P. R. China

^c Southwest University Hospital, Southwest University, Beibei, Chongqing, 400715, China

† Electronic supplementary information (ESI) available: Detailed experimental procedures and materials and Fig. S1–S3. See DOI: 10.1039/c6cc04511a




Fig. 1 Drug release and anticancer effects against MCF-7 and MCF-7/ADR cells. (a) The release profiles of DOX from DMSNs, BGNS in different PBS with pH 7.4 and pH 5.0 at 37 °C. (b and c) Cell viability of MCF-7 cells after incubating with free DOX, DMSNs, or BGNS at different concentrations for 24 h (b) and 48 h (c). (d) Cell viability of MCF-7/ADR cells after incubating with free DOX, DMSNs, or BGNS at different concentrations for 48 h.

was faster than that from DMSNs in PBS at pH 5.0, which simulated lysosomal conditions. These results suggest that upon internalization by cells, BGNS can release DOX faster than DMSNs in acidic intracellular compartments, whereas BGNS showed less drug leakage than DMSNs under normal physiological conditions.

TEM showed a corresponding result with the drug release profile. After incubating DMSNs with PBS at pH 5.0 for 24 h, fewer nanoparticles with a hollow structure could be seen (Fig. S3a, ESI†). However, after incubating BGNS with PBS at pH 5.0 for 24 h, more particles with a hollow structure could be observed (Fig. S3b, ESI†). Treating both DMSNs and BGNS with PBS at pH 7.4 for 24 h led to the observation of almost no hollow structure. For the DMSNs, DOX was adsorbed onto the silica surface mainly *via* electrostatic attraction, and the pH-controlled release was attributed to a decrease in attraction because DOX can exchange with protons under acidic conditions.²¹ For BGNS, DOX was transformed into DOX-HCO₃, which is insoluble in water and neutral solutions. However, BGNS strongly reacted with H⁺ and generated a lot of CO₂ bubbles in PBS at pH 5.0 (Fig. S3b, ESI†). As reported,^{22,23} the generated bubbles accelerated the release of DOX.

To further determine if BGNS could enhance the anticancer efficacy against MCF-7 cells, the cytotoxicity of free DOX, DMSNs, and BGNS was measured by CCK-8 assay at different DOX concentrations. Free DOX, DMSNs, and BGNS all showed dose-dependent toxicity, with BGNS having the highest toxicity (Fig. 1b and c). The half-maximal inhibitory concentration (IC₅₀) of free DOX, DMSNs, and BGNS against MCF-7 cells after 24 h of treatment was 5.51, 4.50, and 3.96 μg mL⁻¹, respectively (Fig. 1b), and after 48 h of treatment was 3.61, 3.35, 2.66 μg mL⁻¹, respectively (Fig. 1c). As expected, the BGNS substantially enhanced the cytotoxicity towards MCF-7 cells.

To investigate the intranuclear distribution of DOX in cells, we used confocal laser scanning microscopy (CLSM) to visualize its

intracellular localization in MCF-7 cells incubated with free DOX, DMSNs, or BGNS. For free DOX and DMSNs, red fluorescence from DOX could be observed in the lysosomes and nuclei within 4 h (Fig. 2a). However, with BGNS, the red fluorescence mostly accumulated in the lysosomes, indicating that little DOX got into the MCF-7 cell nuclei. The distribution of DOX did not change with a longer incubation time (Fig. 2b). Interestingly, the DOX of BGNS always accumulated in the lysosomes rather than in the cell nuclei. It is important that DOX is transported into the cell nuclei to exert its cytotoxicity, because its mechanism of action is to interact with DNA by intercalation and inhibit macromolecular biosynthesis.^{24–26}

Even though the DOX of BGNS accumulated in the lysosomes rather than in the cell nuclei, BGNS killed MCF-7 cells more effectively than DMSNs, which can transport DOX to the nuclei of cancer cells. An interesting question is how BGNS was able to effectively kill cancer cells without the aid of DOX. BGNS can be endocytosed by MCF-7 cells and trapped in lysosomes (Fig. 2). Due to the acidic conditions inside lysosomes, DOX-HCO₃ inside BGNS strongly reacted with H⁺ and generated lots of CO₂ bubbles (Fig. S3b, ESI†).

To investigate the effects of bubbles on the lysosomes, changes in LMP were visualized by fluorescence imaging according to a previously reported method.¹⁴ With increasing LMP, fluorescent




Fig. 2 Cellular colocalization images. (a and b) CLSM images of the intracellular accumulation of DOX in MCF-7 cells after incubating with free DOX (I), DMSNs (II), or BGNS (III) for 4 h (a), 24 h (b).




Fig. 3 Visualization of LMP. ** $p < 0.01$, and *** $p < 0.001$, when comparing drug treated cells with untreated cells (control); and $p < 0.001$, when comparing BGNS treated cells to DMSNs treated cells.

dextran progressed from a punctate lysosomal to diffuse cytosolic staining. Free DOX had almost no effect on changes in LMP, and DMSNs slightly increased LMP due to the “proton sponge” effect (Fig. 3).^{27,28} BGNSs dramatically increased LMP (Fig. 3), which could be attributed to BGNSs acting as explosives as they generated numerous CO₂ bubbles inside the lysosomes of MCF-7 cells.

Increased LMP may cause the release of certain cathepsins from the lysosome into the cytoplasm, and can trigger death by apoptosis and apoptosis-like pathways.¹¹ Caspase-3 is a key executor of apoptosis, the upregulation of active caspase-3 is the evidence of apoptosis.^{29,30} After incubation with free DOX, DMSNs, and BGNS, caspase-3 activity in MCF-7 cells was measured. Free DOX and DMSNs induced a slight increase, whereas BGNS induced the highest increase in caspase-3 activity (Fig. 4). The higher the value of caspase-3, the more apoptosis of cancer cells. These results are in accordance with the cytotoxicity results showing that BGNS had the highest anticancer activity (Fig. 1b and c), and implicated that apoptosis was the mechanism underlying cell death.

Sung's group constructed CO₂ bubble-generating drug delivery systems based on liposome and poly(lactic-co-glycolic acid) (PLGA).^{22,31–34} The PLGA-based system was pH-responsive and can prompt release of DOX once internalized in the lysosome of cancer cells.^{22,31} The liposomal system was thermoresponsive and can prompt release of drugs^{32,33} or lead to cell necrosis³⁴ by generating bubbles when heated locally. Our HMSN-based




Fig. 4 Caspase-3 activities. Cells were incubated with medium (control), free DOX, DMSNs, and BGNS for 48 h. The concentration of DOX was 1 $\mu\text{g mL}^{-1}$. *** $p < 0.001$, when comparing drug treated cells with untreated cells (control); ## $p < 0.01$, when comparing BGNS treated cells to DMSNs treated cells.

BGNS was pH-responsive and can kill cancer cells directly by bubbles without the aid of heat.

Some cancer cells acquire the ability to efflux drugs by increasing the expression of MDR proteins such as P-glycoproteins (P-gps) of the ATP-binding cassette transporter family.² BGNSs can kill cancer cells without the aid of DOX, and as such, are able to overcome the MDR of cancer cells. MCF-7/ADR cells were used to test the toxicity of BGNS. As expected, BGNS substantially enhanced cytotoxicity towards MCF-7/ADR cells (Fig. 1d). The viability of MCF-7/ADR cells did not considerably decrease at low concentrations of free DOX. Even after a 48 h incubation with a relatively high DOX concentration of 16 $\mu\text{g mL}^{-1}$, there was an approximately 70% survival rate of MCF-7/ADR cells. The DMSNs showed limited enhancement of anticancer efficiency compared to free DOX, which might be attributed to the nanoparticle-mediated DOX delivery mechanism to bypass P-gp-mediated efflux.¹⁹ However, only 28% of MCF-7/ADR cells survived when 16 $\mu\text{g mL}^{-1}$ BGNS was incubated with MCF-7/ADR cells for 48 h. Significantly decreased IC₅₀ values of BGNS are shown in Fig. 1d, IC₅₀ of free DOX, DMSNs, BGNS against MCF-7/ADR cells after 48 h treatment were 45.6, 22.5, and 10.6 $\mu\text{g mL}^{-1}$, respectively. These results confirm that BGNS can effectively kill MDR cancer cells.

In summary, we developed and characterized BGNS, which had remarkable anticancer effects against MCF-7 and MCF-7/ADR cells. BGNS could enhance LMP by releasing CO₂ bubbles in the intracellular lysosome, whereas they are stable elsewhere in the body. BGNS showed the greater anticancer effects than free DOX and DMSNs, and may be a potential candidate for overcoming MDR.

This work was supported by the National Key Scientific Program – Nanoscience and Nanotechnology (No. 2011CB933600), the National Natural Science Foundation of China (No. 21175110, 21405124), and the Fundamental Research Funds for the Central Universities (No. XDJK2013A022, XDJK2014C173, XDJK2016E057). The authors thank Prof. Xie Haiyan and Dr Huang Lili (Beijing Institute of Technology) for their assistance with the cellular colocalization imaging experiment.

Notes and references

- 1 G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe and M. M. Gottesman, *Nat. Rev. Drug Discovery*, 2006, 5, 219.
- 2 M. M. Gottesman, T. Fojo and S. E. Bates, *Nat. Rev. Cancer*, 2002, 2, 48.
- 3 H. M. Coley, *Cancer Treat. Rev.*, 2008, 34, 378.
- 4 D. E. Dolmans, D. Fukumura and R. K. Jain, *Nat. Rev. Cancer*, 2003, 3, 380.
- 5 L. Pan, Q. He, J. Liu, Y. Chen, M. Ma, L. Zhang and J. Shi, *J. Am. Chem. Soc.*, 2012, 134, 5722.
- 6 D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit and R. Langer, *Nat. Nanotechnol.*, 2007, 2, 751.
- 7 N. J. Roberts, L. Zhang, F. Janku, A. Collins, R.-Y. Bai, V. Staedtke, A. W. Rusk, D. Tung, M. Miller and J. Roix, *Sci. Transl. Med.*, 2014, 6, 249ra111.
- 8 Y. Lin, H. Zhang, J. Liang, K. Li, W. Zhu, L. Fu, F. Wang, X. Zheng, H. Shi and S. Wu, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, 111, E4504.
- 9 H. Wu, W. N. Hait and J.-M. Yang, *Cancer Res.*, 2003, 63, 1515–1519.
- 10 C. DUVE, *Eur. J. Biochem.*, 1983, 137, 391.
- 11 P. Boya and G. Kroemer, *Oncogene*, 2008, 27, 6434.
- 12 N. Fehrenbacher, L. Bastholm, T. Kirkegaard-Sørensen, B. Rafn, T. Bottzauw, C. Nielsen, E. Weber, S. Shirasawa, T. Kallunki and M. Jäättelä, *Cancer Res.*, 2008, 68, 6623.
- 13 P. Saftig and K. Sandhoff, *Nature*, 2013, 502, 312.

- 14 N. H. Petersen, O. D. Olsen, L. Groth-Pedersen, A.-M. Ellegaard, M. Bilgin, S. Redmer, M. S. Ostenfeld, D. Ulanet, T. H. Dovmark and A. Lønborg, *Cancer cell*, 2013, **24**, 379.
- 15 M. T. Gyparakis and A. G. Papavassiliou, *Trends Mol. Med.*, 2014, **20**, 239.
- 16 Y. Chen, H. R. Chen and J. L. Shi, *Acc. Chem. Res.*, 2013, **47**, 125.
- 17 Y. Chen, H. Chen, D. Zeng, Y. Tian, F. Chen, J. Feng and J. Shi, *ACS Nano*, 2010, **4**, 6001.
- 18 L. Li, F. Tang, H. Liu, T. Liu, N. Hao, D. Chen, X. Teng and J. He, *ACS Nano*, 2010, **4**, 6874.
- 19 T. Liu, L. Li, X. Teng, X. Huang, H. Liu, D. Chen, J. Ren, J. He and F. Tang, *Biomaterials*, 2011, **32**, 1657.
- 20 Y. Gao, Y. Chen, X. Ji, X. He, Q. Yin, Z. Zhang, J. Shi and Y. Li, *ACS Nano*, 2011, **5**, 9788.
- 21 N. S. Singh, H. Kulkarni, L. Pradhan and D. Bahadur, *Nanotechnology*, 2013, **24**, 065101.
- 22 C.-J. Ke, W.-L. Chiang, Z.-X. Liao, H.-L. Chen, P.-S. Lai, J.-S. Sun and H.-W. Sung, *Biomaterials*, 2013, **34**, 1.
- 23 J. Liu, H. Ma and T. Wei, and X. J. Liang, *Chem. Commun.*, 2012, **48**, 4869.
- 24 S. Cai, S. Thati, T. R. Bagby, H. M. Diab, N. M. Davies, M. S. Cohen and M. L. Forrest, *J. Controlled Release*, 2010, **146**, 212.
- 25 R. Palchaudhuri and P. J. Hergenrother, *Curr. Opin. Biotechnol.*, 2007, **18**, 497.
- 26 O. Tacar, P. Sriamornsak and C. R. Dass, *J. Pharmacokinet. Pharmacodyn.*, 2013, **65**, 157–170.
- 27 O. Boussif, F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix and J. P. Behr, *Proc. Natl. Acad. Sci. U. S. A.*, 1995, **92**, 7297.
- 28 I. Slowing, B. G. Trewyn and V. S. Y. Lin, *J. Am. Chem. Soc.*, 2006, **128**, 14792.
- 29 G. Cohen, *Biochem. J.*, 1997, **326**, 1.
- 30 V. A. Movsesyan, A. G. Yakovlev, E. A. Dabaghyan, B. A. Stoica and A. I. Faden, *Biochem. Biophys. Res. Commun.*, 2002, **299**, 201.
- 31 K.-J. Chen, H.-F. Liang, H.-L. Chen, Y. Wang, P.-Y. Cheng, H.-L. Liu, Y. Xia and H.-W. Sung, *Angew. Chem., Int. Ed.*, 2011, **50**, 8086.
- 32 K.-J. Chen, H.-F. Liang, H.-L. Chen, Y. Wang, P.-Y. Cheng, H.-L. Liu, Y. Xia and H.-W. Sung, *ACS Nano*, 2013, **7**, 438.
- 33 K.-J. Chen, E.-Y. Chaung, S.-P. Wey, K.-J. Lin, F. Cheng, C.-C. Lin, H.-L. Liu, H.-W. Tseng, C.-P. Liu, M.-C. Wei, C.-M. Liu and H.-W. Sung, *ACS Nano*, 2014, **8**, 5105.
- 34 M.-F. Chung, K.-J. Chen, H.-F. Liang, Z.-X. Liao, W.-T. Chia, Y. Xia and H.-W. Sung, *Angew. Chem., Int. Ed.*, 2012, **51**, 10089.